MESA LABORATORIES INC /CO/
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
MLAB$127.82-0.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
M****esa Laboratories, Inc.**
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)
| June 30, | March 31, | |
|---|---|---|
| 2025 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $21,279 | $27,321 |
| Accounts receivable, less allowance for credit losses of $1,190 and $1,186, respectively | 39,068 | 41,970 |
| Inventories | 28,106 | 25,365 |
| Prepaid expenses and other current assets | 9,805 | 8,029 |
| Total current assets | 98,258 | 102,685 |
| Noncurrent assets: | ||
| Property, plant and equipment, net of accumulated depreciation of $27,827 and $26,421, respectively | 31,692 | 32,333 |
| Deferred tax asset | 1,474 | 1,371 |
| Other assets | 18,868 | 18,324 |
| Customer relationships, net | 73,524 | 72,880 |
| Other intangibles, net | 23,877 | 23,995 |
| Goodwill | 188,050 | 181,760 |
| Total assets | $435,743 | $433,348 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,270 | $5,747 |
| Accrued payroll and benefits | 10,426 | 17,858 |
| Unearned revenues | 15,077 | 14,710 |
| Other accrued expenses | 16,070 | 24,601 |
| Term loan, current portion | 4,219 | 3,750 |
| Convertible notes, current portion, net of debt issuance costs | 97,432 | 97,297 |
| Total current liabilities | 149,494 | 163,963 |
| Noncurrent liabilities: | ||
| Deferred tax liability | $21,563 | 20,181 |
| Other noncurrent liabilities | 12,657 | 12,472 |
| Term loan, noncurrent portion, net of discounts and debt issuance costs | 65,533 | 66,902 |
| Revolving line of credit | 14,000 | 10,000 |
| Total liabilities | 263,247 | 273,518 |
| Stockholders’ equity: | ||
| Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,501,454 and 5,455,421 shares, respectively | 361,361 | 358,541 |
| (Accumulated deficit) | (185,067) | (188,936) |
| Accumulated other comprehensive (loss) | (3,798) | (9,775) |
| Total stockholders’ equity | 172,496 | 159,830 |
| Total liabilities and stockholders’ equity | $435,743 | $433,348 |
See accompanying notes to Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.